These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 24598096)

  • 1. [Concomitant use of romiplostim and chemotherapy for advanced rectal cancer associated with idiopathic thrombocytopenic purpura].
    Yamada M; Shinzaki S; Nishida T; Yamada T; Fujinaga T; Yakushijin T; Tatsumi T; Iijima H; Hiramatsu N; Tsujii M; Takehara T
    Nihon Shokakibyo Gakkai Zasshi; 2014 Mar; 111(3):521-8. PubMed ID: 24598096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Portal vein thrombosis as complication of romiplostim treatment in a cirrhotic patient with hepatitis C-associated immune thrombocytopenic purpura.
    Dultz G; Kronenberger B; Azizi A; Mihm U; Vogl TJ; Sarrazin U; Sarrazin C; Zeuzem S; Hofmann WP
    J Hepatol; 2011 Jul; 55(1):229-32. PubMed ID: 21310200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of Immune Thrombocytopenic Purpura (ITP) with the thrombopoietin-mimetic romiplostim.
    Meletis J; Katsandris A; Raptis SD; Mantzourani M
    Med Sci Monit; 2010 Aug; 16(8):CS100-2. PubMed ID: 20671616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic dosing of romiplostim in patients with immune thrombocytopenia purpura: Two case reports.
    Gilreath JA; Wei M; Paul S; Parker CJ; Stenehjem DD; Rodgers GM
    J Oncol Pharm Pract; 2019 Apr; 25(3):719-723. PubMed ID: 29357781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP].
    Mori M; Kato M; Koh K; Hanada R
    Rinsho Ketsueki; 2015 May; 56(5):511-3. PubMed ID: 26062675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly fluctuating thrombocytopenia developing in a patient with immune thrombocytopenia (ITP) while administering romiplostim.
    Shinohara K; Kambara N
    Intern Med; 2012; 51(11):1399-401. PubMed ID: 22687850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Case of Multiple Cerebral Infarction Preceding Acute Exacerbation of Idiopathic Thrombocytopenic Purpura.
    Sasaki T; Yasuda T; Abe D; Miyano R; Kainaga M; Tomura N; Kitamura M; Nakayama T; Imafuku I
    J Stroke Cerebrovasc Dis; 2019 Mar; 28(3):789-791. PubMed ID: 30553647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case study of remission in adults with immune thrombocytopenia following cessation of treatment with the thrombopoietin mimetic romiplostim.
    Bussel JB; Wang X; Lopez A; Eisen M
    Hematology; 2016 May; 21(4):257-62. PubMed ID: 26251926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim.
    Cines DB; Gernsheimer T; Wasser J; Godeau B; Provan D; Lyons R; Altomare I; Wang X; Lopez A
    Int J Hematol; 2015 Sep; 102(3):259-70. PubMed ID: 26201709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
    J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials.
    Rodeghiero F; Stasi R; Giagounidis A; Viallard JF; Godeau B; Pabinger I; Cines D; Liebman H; Wang X; Woodard P
    Eur J Haematol; 2013 Nov; 91(5):423-36. PubMed ID: 23927437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥ 65 years with immune thrombocytopenia.
    Michel M; Wasser J; Godeau B; Aledort L; Cooper N; Tomiyama Y; Khellaf M; Wang X
    Ann Hematol; 2015 Dec; 94(12):1973-80. PubMed ID: 26341755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of thrombopoietin receptor agonists on leukocyte and haematopoietic stem and progenitor cells in the peripheral blood of patients with immune thrombocytopenic purpura.
    Bal G; Fabian D; Maia D; Ringel F; Salama A
    Ann Hematol; 2017 Dec; 96(12):2045-2056. PubMed ID: 28965224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of platelet function in adult patients with chronic immune thrombocytopenia on romiplostim treatment.
    Ignatova AA; Demina IA; Ptushkin VV; Khaspekova SG; Shustova ON; Pankrashkina MM; Ryabykh AA; Obydennyi SI; Strelkova OS; Polokhov DM; Seregina EA; Poletaev AV; Ataullakhanov FI; Kireev II; Mazurov AV; Maschan AA; Novichkova GA; Panteleev MA
    Br J Haematol; 2019 Oct; 187(2):e38-e42. PubMed ID: 31422582
    [No Abstract]   [Full Text] [Related]  

  • 15. A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura.
    Shirasugi Y; Ando K; Hashino S; Nagasawa T; Kurata Y; Kishimoto Y; Iwato K; Ohtsu T; Berger DP
    Int J Hematol; 2009 Sep; 90(2):157-165. PubMed ID: 19543952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial Experience with the Use of Thrombopoetin Receptor Agonists in Patients with Refractory HIV-Associated Immune Thrombocytopenic Purpura: A Case Series.
    Kowalczyk M; Rubinstein PG; Aboulafia DM
    J Int Assoc Provid AIDS Care; 2015; 14(3):211-6. PubMed ID: 25504472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of eltrombopag after romiplostim in primary immune thrombocytopenia.
    González-Porras JR; Mingot-Castellano ME; Andrade MM; Alonso R; Caparrós I; Arratibel MC; Fernández-Fuertes F; Cortti MJ; Pascual C; Sánchez-González B; Bernat S; Fuertes-Palacio MA; Vázquez-Paganini JA; Olivera PE; Alvarez-Román MT; Jarque I; Cortés M; Martínez-Robles V; Díaz-Gálvez FJ; Calbacho M; Fernández-Miñano C; Garcia-Frade J; González-López TJ
    Br J Haematol; 2015 Apr; 169(1):111-6. PubMed ID: 25521630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association of rituximab and a thrombopoietin receptor agonist in high-risk refractory immune thrombocytopenic purpura.
    Veneri D; Soligo L; Pizzolo G; Ambrosetti A
    Blood Transfus; 2015 Oct; 13(4):694-5. PubMed ID: 26057496
    [No Abstract]   [Full Text] [Related]  

  • 19. Romiplostim in chronic immune thrombocytopenic purpura.
    Cersosimo RJ
    Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of romiplostim and rituximab: effective therapy of severe immune thrombocytopenia.
    Pohlen M; Sargin B; Zicholl S; Bisping G; Müller-Tidow C; Berdel WE; Mesters R; Koschmieder S
    Eur J Haematol; 2010 Apr; 84(4):362-4. PubMed ID: 20050881
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.